Cargando…
Olaparib treatment in older patients with ovarian cancer: need for ‘real-world’ data beyond clinical trials
BACKGROUND: Ageing is a risk factor for cancer. Worldwide, the number and proportion of adults aged ≥65 will increase, along with the incidence of ovarian cancer. Older adults are under-represented in randomised clinical trials (RCTs), and those who are enrolled have a good performance status and no...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532029/ https://www.ncbi.nlm.nih.gov/pubmed/33082854 http://dx.doi.org/10.3332/ecancer.2020.1104 |